Company Profile: BioMedomics, Inc.

CED Life Science Conference 2017 - Lightning Round & Innovation Room                                                
Sub-sector: Diagnostic                                                                
Year Founded: 2006

BioMedomics, Inc. is a point-of-care (“POC”) diagnostics company focused on unique immunologically based disease specific tests and advanced highly sensitive quantitative POC platforms. The company was founded in the end of 2006 as a Delaware Corporation and located in the Research Triangle Park, North Carolina. The Company has already developed novel POC tests for Sickle Cell Disease (Sickle SCAN) and Alpha Thalassemia (alpha-Thal SCAN) that have received CE Mark approval and are currently being launched to medical diagnostic market. Additionally, we are preparing to launch a novel POC quantitative test for hemoglobin S (HbS) that is used in the treatment of SCD. The Company has also licensed a total hemoglobin monitor (Hemo SCAN), which is a compliment to these hemoglobinopathy tests.

Dr. Frank Wang, CEO
Christopher Kelly, CFO
Dr. Linxian Wu, COO
Dr. Jason Kim, Vice President of Product Development and Technology
Christopher Trout, International Sales Manager


  • Funding: Approximately $7.5MM
  • Production of our Sickle SCAN tests from our contract manufacturers has reached a high volume
  • Successfully obtained ISO 13485 Certificate
  • HbS test has been CE Mark approved, approval for HbF test is underway
  • Full patent submission for the alpha-Thal SCAN technology
  • Our next test product for Beta Thalassemia disease diagnosis has made significant progress

CED, Hammer Institute, NC Biotechnology Center, NC IDEA, SBTDC, Southeast Bio

Frank Wang
Durham, NC

Learn more about the CED Life Science Conference.